Bevacizumab (Bev) with or without erlotinib as maintenance therapy, in patients (pts) with metastatic colorectal cancer (mCRC): Exploratory analysis according to KRAS status in the gercor DREAM phase III trial

被引：0
|
作者：
Samson, Benoit
Tournigand, Christophe
Scheithauer, Werner
Lledo, Gerard
Viret, Frederic
Andre, Thierry
Ramee, Jean Francois
Tubiana-Mathieu, Nicole
Dauba, Jerome
Dupuis, Olivier
Rinaldi, Yves
Mabro, May
Aucoin, Nathalie
Khalil, Ahmed
Latreille, Jean
Louvet, Christophe
Brusquant, David
Bonnetain, Franck
Chibaudel, Benoist
De Gramont, Aimery
机构：
[1] Hop Charles LeMoyne, Quebec City, PQ, Canada
[2] Hop Henri Mondor, F-94010 Creteil, France
[3] Med Univ Vienna, Vienna, Austria
[4] Hop Prive Jean Mermoz, Lyon, France
[5] Inst J Paoli I Calmettes, F-13009 Marseille, France
[6] Hop St Antoine, F-75571 Paris, France
[7] Ctr Catherine Sienne, Nantes, France
[8] CHU Limoges, Limoges, France
[9] Ctr Hosp Layne, Mt De Marsan, France
[10] Clin Victor Hugo, Le Mans, France
[11] Hop Ambroise Pare, Marseille, France
[12] Hop Foch, Suresnes, France
[13] Cite Sante Laval, Laval, PQ, Canada
[14] Hop Tenon, F-75970 Paris, France
[15] Hop Charles LeMoyne, Greenfield Pk, PQ, Canada
[16] Inst Mutualiste Montsouris, Dept Oncol, Paris, France
[17] GERCOR, Paris, France
[18] CHU Besancon, F-25030 Besancon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.448
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
448
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial
    Salvatore, Lisa
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Bergamo, Francesca
    Gallano, Antonella
    Zagonel, Vittorina
    Ferrari, Laura
    Ongaro, Elena
    Cardellino, Giovanni
    Marcucci, Lorenzo
    Lucchesi, Sara
    Banzi, Maria
    Ciarlo, Andrea
    Miraglio, Emanuele
    Delfanti, Sara
    Corsi, Domenico C.
    Zaniboni, Alberto
    Tonlni, Giuseppe
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [32] Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial-Comparison of the efficacy of KRAS status
    Nakamura, Michio
    Yuki, Satoshi
    Dazai, Masayoshi
    Kobayashi, Yoshimitsu
    Kato, Takashi
    Naruse, Hirohito
    Kudo, Mineo
    Akakura, Nobuaki
    Sakata, Yuh
    Komatsu, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [33] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
    Loupakis, Fotios
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Falcone, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [34] Analysis of Blood Plasma Factors in the AVITA Phase III Randomized Study of Bevacizumab (bev) With Gemcitabine-Erlotinib (GE) in Patients (pts) With Metastatic Pancreatic Cancer (mPC)
    Van Cutsem, E.
    Jayson, G.
    Dive, C.
    Dilba, P.
    de Haas, S.
    Wild, N.
    Delmar, P.
    Scherer, S. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S95 - S96
  • [35] Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC)
    Kasubhai, Saifuddin M.
    Bendell, Johanna C.
    Kozloff, Mark
    Kapp, Amy V.
    Ashkenazi, Avi
    Royer-Joo, Stephanie
    Portera, Chia C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [36] IND.210: A randomized phase 2 trial of FOLFOX6/bevacizumab with or without reovirus (Reo) in patients (pts) with metastatic colorectal cancer (mCRC).
    Tang, Patricia A.
    Jonker, Derek J.
    Kennecke, Hagen F.
    Welch, Stephen
    Cripps, M. Christine
    Asmis, Timothy R.
    Chalchal, Haji I.
    Tomiak, Anna T.
    Ko, Yoo-Joung
    Chen, Eric
    Alcindor, Thierry
    Goffin, John R.
    Theis, Ashley
    Gill, George M.
    Tu, Dongsheng
    Seymour, Lesley
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] Modified (m) Folfox7/bevacizumab (B) or modified (m) Xelox/bevacizumab with or without erlotinib (E) in first-line metastatic colorectal cancer (MCRC): Results of the feasibility phase of the DREAM-OPTIMOX3 study (GERCOR)
    Tournigand, C.
    Lledo, G.
    Delord, J.
    Andre, T.
    Maindrault-Goebel, F.
    Louvet, C.
    Scheithauer, W.
    de Gramont, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] OXALIPLATIN AND CAPECITABINE (XELOX) PLUS BEVACIZUMAB (BEVA) FOR ELDERLY PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC): BOXE, A PHASE II TRIAL
    Rosati, Gerardo
    Cordio, Stefano
    Leo, Silvana
    Daniele, Bruno
    Butera, Alfredo
    ANNALS OF ONCOLOGY, 2011, 22 : v104 - v104
  • [39] Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis
    Wei Xu
    Yang Gong
    Meng Kuang
    Peng Wu
    Chunxiang Cao
    Jinfei Chen
    Cuiju Tang
    Clinical Drug Investigation, 2017, 37 : 155 - 165
  • [40] Survival Benefit and Safety of Bevacizumab in Combination with Erlotinib as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: A Meta-Analysis
    Xu, Wei
    Gong, Yang
    Kuang, Meng
    Wu, Peng
    Cao, Chunxiang
    Chen, Jinfei
    Tang, Cuiju
    CLINICAL DRUG INVESTIGATION, 2017, 37 (02) : 155 - 165
12345